Peh, Jessie <br/><br/>
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.  [electronic resource] 

 -  Molecular cancer therapeutics  08 2016 
 - 1859-69 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-16-0025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Disease Models, Animal<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Humans<br/>Hydrazones--pharmacology<br/>Indoles--pharmacology<br/>Melanoma--drug therapy<br/>Mice<br/>Mutation<br/>Phosphorylation<br/>Piperazines--pharmacology<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Sulfonamides--pharmacology<br/>Tumor Burden--drug effects<br/>Vemurafenib<br/>Xenograft Model Antitumor Assays